fda deadline semaglutide crackdown on off-brand Ozempic products set to take effect, threatening supply and access for many Semaglutide Shortage Ends: What Patients

Retatrutide creates a window of opportunity for fat loss, not a permanent solution

The answer is yes: clinical trials show semaglutide produces meaningful weight loss across the spectrum, with average reductions ranging from 5% to 15% of body weight depending on dose and adherence

It is a deadline

The FDA-approved labeling for GLP-1 medications lists gastrointestinal symptoms as the most frequent adverse reactions, but comprehensive tracking should capture the full spectrum of potential effects

Orlando, Castagno D, Baird-Gunning J, Jhund PS, et Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis